Legend Biotech stock analysis
Legend Biotech (9LB) Stock Price & Analysis
9LB Stock Chart & Stats
- Day’s Range
- EUR 17.80 - EUR 20.40
- 52-Week Range
- EUR 13.80 - EUR 31.20
- Previous Close
- EUR 21.00
- Volume
- N/A
- Average Volume (3M)
- 13
- Market Cap
- EUR 4.04B
- Enterprise Value
- EUR 4.91B
- Total Cash (Recent Filing)
- EUR 964.63M
- Total Debt (Recent Filing)
- EUR 278.21M
- Price to Earnings (P/E)
- ―
- Beta
- 0.61
- Next Earnings
- Mar 16, 2027 (Est.)
- EPS Estimate
- 0.04
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
CARVYKTI Commercial Growth
Strong CARVYKTI growth across U.S. and international markets indicates expanding product adoption and commercial reach. Rising earlier-line use, new country launches, and broader treatment access can support sustained revenue growth and improve operating leverage over the next several quarters.
Clinical Differentiation
Long-term progression-free survival after a single infusion provides important evidence for CARVYKTI’s clinical durability. Combined with updated NCCN guidance preferring CAR-T in relevant settings, these results may strengthen physician adoption and support expansion into earlier treatment lines.
Improving Profitability And Capitalization
The return to adjusted profitability, stronger gross margin, and debt-free liquidity indicate improving operating leverage and financial flexibility. This gives Legend more capacity to fund commercial expansion and pipeline development while reducing reliance on additional financing as the business scales.
Bears Say
Persistent Cash Burn
Despite improving earnings, Legend remains cash-flow negative, showing that the business is not yet consistently self-funding. Continued operating and development outflows could require use of liquidity or external financing, limiting flexibility if profitability progress slows.
Competitive And Adoption Pressure
Competition from bispecifics and rival CAR-T therapies can pressure CARVYKTI’s market share, pricing power, and physician adoption. The slower U.S. shift into earlier-line treatment also suggests that expanding the addressable market may require longer education and referral cycles.
Dependence On CARVYKTI And Partnership Execution
The company’s revenue model remains heavily tied to one partnered commercial product and the execution of its Janssen collaboration. This concentration increases exposure to CARVYKTI demand, launch timing, partnership economics, and any disruption to the product’s commercial trajectory.
9LB FAQ
What was Legend Biotech’s price range in the past 12 months?
What is Legend Biotech’s market cap?
When is Legend Biotech’s upcoming earnings report date?
How were Legend Biotech’s earnings last quarter?
Is Legend Biotech overvalued?
Does Legend Biotech pay dividends?
What is Legend Biotech’s EPS estimate?
How many shares outstanding does Legend Biotech have?
What happened to Legend Biotech’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Legend Biotech?
What is the TipRanks Smart Score and how is it calculated?
Legend Biotech Stock Smart Score
Company Description
Legend Biotech
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alan S. Bash
- Employees
- 3,200
- Website
- www.legendbiotech.com
- Address
- 2101 Cottontail Lane, Somerset, NJ, 08873, US
Legend Biotech (9LB) Earnings & Revenues
9LB Company Deck
9LB Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. CARVYKTI delivered 36% year-over-year net trade sales growth, international growth was 86%, earlier-line adoption continued to expand, long-term clinical data remained favorable, LB2501 showed encouraging early activity, and profitability and operating leverage improved materially. The main challenges were slower-than-anticipated earlier-line growth in the U.S., international launch delays, increasing competition from bispecifics and other CAR-T therapies, and event-driven timing for later-stage clinical readouts.
View all DE:9LB earnings summaries9LB Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 3 | 4 |
| Technical Analysis | 2 | 3 | 4 |
| Moving Averages | 12 | 0 | 0 |
